Target Audience
This series of activities is designed for gastroenterologists, hepatologists, infectious disease specialists, internal medicine and primary care providers, nurse practitioners, nurses, physician assistants, and pharmacists who specialize in and care for patients with HBV.
Activity Goal
The goal of Chronic Hepatitis B: The Advanced Curriculum is to increase clinicians’ awareness of HBV disease prevalence, prevention strategies, and screening and diagnostic methodology within the high-risk HBV patient populations; bridge cultural differences in communicating diagnosis and treatment; provide current and emerging strategies for the selection of patients for treatment; educate clinicians on current treatment options; and expand on treatment management skills for HBV-infected patients.
Learning Objective (s)
- Analyze the disease burden posed by HBV and assess the importance of implementing early screening and diagnosis of patients for HBV infection.
- Evaluate and address cultural/language barriers to optimal screening, diagnosis, and treatment of HBV in high-risk groups (eg, Asian-Pacific Islanders, Latinos, and others).
- Evaluate the clinical relevance/thresholds for HBV tests to determine who and when to treat, optimal treatment selection, and on-treatment response to therapy.
- Evaluate anti-HBV treatment guidelines to determine optimal screening, diagnosis, and treatment recommendations.
- Formulate anti-HBV treatment strategies based on efficacy, safety, and resistance profiles of treatments, monitor and manage treatment response/resistance, and, if necessary, determine when to switch and when to add on treatments to optimize patient outcomes.
- Implement optimal treatment selection for special populations (transplants, immune compromised, pregnant, etc).
- Analyze how HBV leads to hepatocellular carcinoma and/or cirrhosis.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Specific credit information can be found on each activity's web page.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Abbott Laboratories, Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Tibotec Pharmaceuticals, Ltd, Transgene Biotek Ltd, and Vertex Pharmaceuticals Inc; is a consultant for and/or on the advisory board of Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Hoffmann-La Roche, Ltd, Merck & Co., Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Salix Pharmaceuticals, Inc, Tibotec Pharmaceuticals, Ltd, and Vertex Pharmaceuticals Incorporated; and is a member of the data safety monitoring boards of Anadys Pharmaceuticals, Inc, and Bayer AG
Robert G. Gish, MD has received grant/research support through an institutional fund under contract to the University of California San Diego research program from Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer/Onyx, Bristol-Myers Squibb, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, Merck & Co, Inc, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; is a consultant for Abbott Laboratories, Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb, DURECT Corporation, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, HepaHope, Inc, Kadmon Corporation, LLC, Merck & Co, Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Schering-Plough Corporation, and VitalTherapies [funds directed to a UCSD SPF fund for research and education]; is on the speakers bureau of Bayer Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche, Ltd, Merck & Co, Inc/Schering-Plough Corporation, Onyx Pharmaceuticals, Inc, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, SciClone Pharmaceuticals, and Three Rivers Pharmaceuticals [funds, except for Merck and Vertex, directed to a UCSD SPF fund for research and education]; is a major stock shareholder of HepaHope, Inc, and a minor stock shareholder of Kinex Pharmaceuticals.
Kris V. Kowdley, MD has received grant/research support from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc, Merck & Co, Inc, Mochida Pharmaceutical Co, Ltd, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; and has received consulting fees from Abbott Laboratories, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.
Helen S. Te, MD has disclosed no significant relationships.
Hashem B. El-Serag, MD, MPH has received grant/research support from Abbott Laboratories.
Albert D. Min, MD has received grant/research support, honoraria, and fees for non-CME services from Bristol-Myers Squibb, Gilead Sciences, Inc, Salix Pharmaceuticals, Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees and/or is on the advisory board of Bayer Corporation, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.
The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.